Matching articles for "skin cancer"
Issue 1731 · June 23, 2025 Free
Sunscreens

Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In…

Med Lett Drugs Ther. 2025 Jun 23; 67(1731):97-102 doi:10.58347/tml.2025.1731a
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Issue 1722 · February 17, 2025
Cosibelimab (Unloxcyt) for Cutaneous Squamous Cell Carcinoma (online only)

Cosibelimab ( Unloxcyt – Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, has been approved by the FDA for treatment of locally advanced or metastatic cutaneous squamous cell…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):e32-3 doi:10.58347/tml.2025.1722g
Cosibelimab ( Unloxcyt – Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, has been approved by the FDA for treatment of locally advanced or metastatic cutaneous squamous cell carcinoma in adults who are not candidates for curative surgery or radiation. It is the first PD-L1 inhibitor to be approved in the US for this indication. The PD-1 inhibitors pembrolizumab (Keytruda) and cemiplimab (Libtayo) are also approved for treatment of cutaneous squamous cell carcinoma.
Issue 1668 · January 23, 2023
Opdualag for Metastatic Melanoma (online only)

Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3)…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):e19-20 doi:10.58347/tml.2023.1668g
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old. Relatlimab, which is only available in combination with nivolumab, is the first LAG-3 blocking antibody to become available in the US. Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab (Yervoy) and the PD-1 inhibitors nivolumab and pembrolizumab (Keytruda) , have been available for several years for treatment of melanoma.
Issue 1629 · July 26, 2021 Free
Sunscreens

Excessive exposure to ultraviolet (UV) radiation is associated with sunburn, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):115-20
Excessive exposure to ultraviolet (UV) radiation is associated with sunburn, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. The FDA has issued a proposed rule that would require manufacturers to perform additional safety studies for some sunscreen active ingredients and would mandate better UVA protection in sunscreen products. Some sunscreen products containing FDA-approved active ingredients are listed in Table 2.
Issue 1611 · November 16, 2020 Free
In Brief: Hydrochlorothiazide and Skin Cancer

The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the…

Med Lett Drugs Ther. 2020 Nov 16; 62(1611):177
The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide.
Issue 1553 · August 13, 2018
Sunscreens

Excessive exposure to ultraviolet (UV) radiation is associated with sunburn, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but some questions remain about their effectiveness…

Med Lett Drugs Ther. 2018 Aug 13; 60(1553):129-32
Excessive exposure to ultraviolet (UV) radiation is associated with sunburn, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but some questions remain about their effectiveness and safety.
Issue 1525 · July 17, 2017 Free
In Brief: Avelumab (Bavencio) for Metastatic Merkel Cell Carcinoma (online only)

The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab ( Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in patients ≥12…

Med Lett Drugs Ther. 2017 Jul 17; 59(1525):e120
The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab ( Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in patients ≥12 years old. Avelumab is the first drug to be approved in the US for this rare skin cancer. About 1600 people in the US, most commonly older adults (mean age at presentation is 75 years), are diagnosed each year with MCC. Most of these patients can be treated with surgical resection, but ~50% will have a recurrence and >30% will eventually have metastatic disease. Median progression-free survival in patients with metastatic disease has been about 3 months with chemotherapy. MCC tumors, which often express PD-L1, have been treated offlabel with the PD-1 inhibitors pembrolizumab (Keytruda) 1 and nivolumab (Opdivo) . 2 In an ongoing single-arm trial (JAVELIN Merkel 200), 88 patients with metastatic MCC (58 with PD-L1 positive tumors, 16 PD-L1 negative, 14 not assessable) who were previously treated with at least one chemotherapy regimen received at least one dose of avelumab; 75% of patients were 65 years or older. An objective response occurred in 28 patients (32%); 8 patients had a complete response. Tumor PD-L1 expression did not affect response rates. The duration of response was ≥6 months in 92% of responders. 3 The most common adverse effects of avelumab in clinical trials were fatigue (50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%), rash (22%), and infusion-site reactions (22%). Serious treatment-related adverse events occurred in 6% of patients. Grade 3 or 4 adverse events (lymphopenia, elevation of creatine kinase, transaminase increases) occurred in 5% of patients. As with PD-1 inhibitors, immune-mediated adverse effects including pneumonitis, colitis, nephritis, hepatitis, and endocrinopathies (hypothyroidism, adrenal insufficiency, type 1 diabetes) can occur. The recommended dosage of Bavencio is 10 mg/kg infused IV over 60 minutes every 2 weeks. The cost of one 10-mL vial containing 200 mg of the drug is $1504; three months' treatment for a 60-kg patient would cost $27,072. 4 PT Nghiem et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374:2542. K Mantripragada and A Birnbaum. Response to anti-PD-1 therapy in metastatic Merkel cell carcinoma metastatic to the heart and pancreas. Cureus 2015; 7:e403. HL Kaufman et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17:1374. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy. Download complete U.S. English article
Issue 1422 · August 5, 2013
Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma

The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib ( Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib ( Mekinist –…

Med Lett Drugs Ther. 2013 Aug 5; 55(1422):62-3
The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib ( Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib ( Mekinist – GSK) for melanomas with either BRAF V600E or V600K mutations. Dabrafenib is not recommended for patients with wild-type BRAF (BRAF-negative) melanoma, and trametinib is not recommended for patients who have received prior BRAF-inhibitor therapy.
Issue 1394 · July 9, 2012
Vismodegib (Erivedge) for Basal Cell Carcinoma

The FDA has approved vismodegib (vis moe deg´ ib; Erivedge – Genentech), the first hedgehog (Hh) pathway inhibitor, for oral treatment of metastatic basal cell cancer, locally advanced basal cell carcinoma…

Med Lett Drugs Ther. 2012 Jul 9; 54(1394):53-4
The FDA has approved vismodegib (vis moe deg´ ib; Erivedge – Genentech), the first hedgehog (Hh) pathway inhibitor, for oral treatment of metastatic basal cell cancer, locally advanced basal cell carcinoma that has recurred after surgery, or locally advanced basal cell carcinoma in adults who are not candidates for surgery or radiation.
Issue 1374 · October 3, 2011
Vemurafenib (Zelboraf) for Metastatic Melanoma

The FDA has approved vemurafenib ( Zelboraf – Genentech), a kinase inhibitor, for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation, which is found in 30-60% of melanomas. An…

Med Lett Drugs Ther. 2011 Oct 3; 53(1374):77-8
The FDA has approved vemurafenib ( Zelboraf – Genentech), a kinase inhibitor, for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation, which is found in 30-60% of melanomas. An FDA-approved test can detect the mutation in DNA from melanoma tissue.
Issue 1372 · September 5, 2011
Screening for Melanoma

In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body examination for…

Med Lett Drugs Ther. 2011 Sep 5; 53(1372):72
In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body examination for melanoma and other skin cancers.
Issue 1367 · June 27, 2011
Ipilimumab (Yervoy) for Metastatic Melanoma

The FDA has approved ipilimumab ( Yervoy – Bristol-Myers Squibb), a recombinant human monoclonal antibody, for treatment of unresectable or metastatic melanoma.

Med Lett Drugs Ther. 2011 Jun 27; 53(1367):51-2
The FDA has approved ipilimumab ( Yervoy – Bristol-Myers Squibb), a recombinant human monoclonal antibody, for treatment of unresectable or metastatic melanoma.
Issue 1359 · March 7, 2011
Sunscreens Revisited

Sunscreens are widely used now, but some questions remain about their effectiveness and safety.

Med Lett Drugs Ther. 2011 Mar 7; 53(1359):17-8
Sunscreens are widely used now, but some questions remain about their effectiveness and safety.
Issue 1294 · September 8, 2008
Sunscreens: An Update

Sunscreens are an important component of photoprotection. A new definition of their effectiveness has been proposed, and some issues have arisen concerning their safety.

Med Lett Drugs Ther. 2008 Sep 8; 50(1294):70-2
Sunscreens are an important component of photoprotection. A new definition of their effectiveness has been proposed, and some issues have arisen concerning their safety.
Issue 1261 · May 20, 2007
A New Sunscreen Agent

Ecamsule (terephthalylidene dicamphor sulfonic acid), the first new sunscreen agent to be approved by the FDA in 18 years, is now available in the US in a moisturizer called Anthelios SX . Ecamsule has been…

Med Lett Drugs Ther. 2007 May 20; 49(1261):41-3
Ecamsule (terephthalylidene dicamphor sulfonic acid), the first new sunscreen agent to be approved by the FDA in 18 years, is now available in the US in a moisturizer called Anthelios SX . Ecamsule has been used in Canada and Europe for more than 10 years.